This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Chromophobe cell carcinoma of kidney
C3_KIDNEY_CHROMOPHOBE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
162 |
4. Check minimum number of eventsNone |
162 |
5. Include endpointsNone |
162 |
6. Filter based on genotype QC (FinnGen only) |
162 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF9
- Name in latin
- Carcinoma in situ labii (oris)
Similar endpoints
↥List of similar endpoints to
Chromophobe cell carcinoma of kidney
based on the number of shared cases.
Similar with more cases:
- Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
- Renal cell carcinoma of kidney
- Renal cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of kidney, except renal pelvis
- Malignant neoplasm of urinary organs
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 162 | 57 | 105 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 67.60 | 63.46 | 69.86 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 151
- Matched controls
- 1510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8317/3-C64.9
ICD-O-3
Renal cell carcinoma, chromophobe type of kidney, NOS
+∞
218.2
151
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
1606.8
174.7
140
11
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
547.4
146.9
127
14
KAD01
NOMESCO Finland
Percutaneous endoscopic partial nephrectomy
+∞
40.4
37
*
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
134.8
38.9
40
*
KAD00
NOMESCO Finland
Partial nephrectomy
405.3
33.2
32
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
36.4
25.3
32
11
JN4AD
NOMESCO Finland
Body CT examination
12.6
23.1
43
46
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
14.6
22.6
39
35
B01AB10
ATC
tinzaparin; parenteral
12.5
22.5
42
45
KAC10
NOMESCO Finland
Total nephrectomy with capsule
70.7
21.6
24
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.8
17.7
82
299
WX302
NOMESCO Finland
Thoracal epidural anesthesy
11.1
17.0
33
37
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.7
15.5
50
121
JN4CD
NOMESCO Finland
Very extensive body CT
9.7
14.1
29
36
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
82.4
13.8
15
*
U75
ICPC
Malignant neoplasm of kidney
+∞
13.7
13
*
B01AB05
ATC
enoxaparin; parenteral
3.8
13.3
78
330
TPH07
NOMESCO Finland
Cathetrisation of artery
5.4
12.7
41
97
KA1AE
NOMESCO Finland
Kidney ultrasound examination
15.1
12.3
20
15
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
11.6
98
533
JN4BD
NOMESCO Finland
Extensive body CT
4.8
10.9
39
102
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
95.1
8.5
9
*
N02BE01
ATC
paracetamol; systemic, rectal
5.2
8.2
142
1134
WX402
NOMESCO Finland
General anaesthesia
3.4
7.5
38
134
N02AX02
ATC
tramadol; systemic, rectal
2.6
7.5
85
497
R4110
NOMESCO Finland
Physiotherapy
2.7
6.6
55
267
L01XE04
ATC
[U] sunitinib; oral
72.7
6.5
7
*
KA3LT
NOMESCO Finland
Njurlesion coagulation
72.7
6.5
7
*
197
Kela drug reimbursment
Sunitinib
72.7
6.5
7
*
KAC00
NOMESCO Finland
Nephrectomy
72.7
6.5
7
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
19.0
6.3
9
5
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.9
6.3
42
179
ZXA00
NOMESCO Finland
Right side
2.5
6.1
54
271
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
128
632
5.89
21.66
4.0
4.1
—
—
—
0
0
123
660
4.59
16.80
9.7
5.8
1.2
1.2
mmol/l
1.38
115
601
105
534
3.75
14.81
4.5
3.1
—
—
—
0
0
113
632
3.61
13.13
7.2
4.7
35.5
35.4
g/l
0.10
106
601
52
181
3.76
12.90
6.5
7.5
-0.7
1.2
mmol/l
3.07
43
153
117
709
3.34
11.11
10.3
6.8
1.2
1.2
mmol/l
0.84
96
603
82
421
2.92
10.24
4.3
3.0
0.1
0.4
e6/l
4.12
67
318
48
184
3.29
10.00
8.9
6.0
1.0
1.0
mmol/l
0.00
43
170
150
1105
5.83
9.79
12.0
7.7
81.9
77.8
u/l
0.48
144
1038
58
257
2.96
9.34
3.7
2.7
0.5
0.9
e6/l
1.23
35
153
67
345
2.61
7.86
2.5
2.5
—
—
—
0
0
52
244
2.67
7.28
3.7
2.8
1.0
1.6
e6/l
0.33
29
142
76
453
2.28
6.12
5.5
3.7
2.4
2.3
mmol/l
1.12
66
399
111
803
2.21
5.21
11.0
9.3
4.1
4.2
e9/l
0.23
96
700
155
1360
4.23
4.86
20.8
15.6
34.9
23.5
mg/l
3.10
145
1097
33
158
2.37
4.26
2.1
3.3
—
—
—
0
0
45
247
2.14
4.19
1.7
1.9
30.1
29.6
s
0.37
45
237
48
279
2.02
3.81
5.1
3.1
2.5
2.4
mmol/l
0.92
43
251
8
12
6.95
3.72
1.4
1.3
—
—
—
0
0
38
208
2.08
3.52
4.4
2.4
25.9
22.7
%
0.77
31
182
123
1017
1.87
2.92
4.6
4.2
15.3
12.8
mm/h
0.96
114
933
23
114
2.19
2.72
3.7
2.3
49.7
62.3
ml/min/173m2
1.36
15
41
74
546
1.65
2.52
3.1
2.2
82.4
76.5
nmol/l
0.90
68
483
146
1305
2.20
2.40
25.8
14.8
63.2
77.6
ml/min/173m2
10.55
137
1083
85
672
1.56
2.05
4.4
3.6
0.0
0.0
estimate
0.00
25
115
71
543
1.55
1.96
3.6
2.6
274.9
139.7
ug/l
1.02
62
502
8
27
3.06
1.96
1.5
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
52
2.41
1.93
1.3
2.2
0.3
0.4
u/ml
—
5
30
51
363
1.59
1.92
5.2
4.1
0.0
0.0
estimate
0.00
23
117
83
660
1.53
1.91
5.5
4.8
0.0
0.0
estimate
0.00
24
124
155
1457
2.48
1.79
14.6
11.1
26.1
26.7
u/l
0.14
150
1405
25
150
1.79
1.76
6.7
4.2
6.0
5.7
kpa
0.81
25
143
5
13
3.93
1.73
1.0
1.3
—
—
—
0
0
147
1351
1.95
1.70
5.2
4.9
4.4
4.5
mmol/l
0.22
135
1234
53
394
1.51
1.62
4.3
2.8
396.8
7074.4
umol/l
1.66
45
336
81
658
1.46
1.59
4.5
3.6
0.0
0.0
estimate
0.00
25
125
26
163
1.71
1.58
3.2
5.2
5.0
32.7
ug/l
0.56
18
138
26
163
1.71
1.58
1.4
1.8
—
—
—
0
0
145
1341
1.77
1.43
5.1
4.9
1.4
1.4
mmol/l
0.81
132
1210
5
17
3.00
1.37
1.0
1.3
—
—
—
0
0
11
55
2.07
1.30
2.1
1.8
2.8
0.2
g/l
0.59
11
50
112
989
1.43
1.28
4.7
3.7
15.1
14.9
pmol/l
0.53
103
876
148
1385
1.79
1.27
5.7
5.5
2.6
2.6
mmol/l
0.09
133
1255
33
234
1.52
1.24
1.6
1.9
—
—
—
0
0
144
1343
1.65
1.19
5.6
5.0
6.2
6.1
mmol/l
0.12
134
1218
141
1309
1.60
1.18
4.5
4.4
1.4
1.3
mmol/l
0.63
128
1178
19
119
1.68
1.18
3.2
3.3
323.4
191.1
ng/l
0.46
19
109
58
465
1.39
1.14
3.8
3.3
2104.4
1345.3
ng/l
0.48
52
391
37
274
1.45
1.13
1.5
1.6
1.4
1.3
mg/l
0.13
27
221
7
31
2.31
1.12
1.4
1.3
—
—
—
0
0
134
1239
1.47
1.05
5.6
4.5
1.9
2.0
mu/l
0.08
121
1107
24
167
1.51
0.99
1.5
1.9
—
—
—
0
0
52
420
1.35
0.96
3.1
3.0
0.7
0.8
ug/l
0.47
39
273
13
78
1.72
0.94
1.8
1.3
—
—
—
0
0
81
705
1.30
0.88
2.3
2.5
—
—
—
0
0
44
352
1.34
0.86
2.8
1.9
3.1
3.2
mg/l
0.09
35
308
6
32
1.91
0.82
1.2
1.3
—
—
—
0
0
6
32
1.91
0.82
1.2
1.3
—
—
—
0
0
11
66
1.72
0.81
2.1
1.7
—
—
—
0
0
140
1322
1.43
0.80
6.8
6.5
39.8
41.0
mmol/mol
0.92
131
1223
44
356
1.32
0.80
1.7
1.6
15.3
20.5
nmol/l
2.18
37
301
8
48
1.70
0.80
3.6
3.7
23.4
31.4
mg/l
—
8
40
8
48
1.70
0.80
3.1
3.5
—
4.3
—
0
5
8
48
1.70
0.80
3.6
3.7
78.6
207.5
mg/l
—
8
40
38
302
1.34
0.78
1.7
1.6
1297.0
1203.6
nmol/l
0.22
24
232
60
510
1.28
0.76
4.8
3.9
—
—
—
0
0
9
55
1.67
0.75
1.6
1.8
37.5
37.8
g/l
—
9
47
25
187
1.40
0.74
10.2
8.0
—
—
—
0
0
5
25
2.03
0.73
1.8
1.3
—
—
—
0
0
81
717
1.26
0.73
5.5
5.0
4.6
2.6
ug/l
0.35
74
638
47
390
1.29
0.71
2.1
1.7
1.5
1.3
mmol/l
0.42
38
320
127
1189
1.32
0.70
27.9
16.3
38.6
40.0
%
0.97
87
819
66
576
1.25
0.66
4.2
4.4
22.5
22.1
%
0.07
35
274
18
130
1.43
0.64
1.2
1.3
—
—
—
0
0
25
193
1.35
0.62
1.0
1.3
4.7
9.1
u/ml
—
10
69
0
20
0.00
0.61
0.0
1.2
—
7.4
—
0
13
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
6
36
1.69
0.57
2.2
1.5
—
—
—
0
0
6
38
1.60
0.55
1.5
1.2
—
—
—
0
0
12
83
1.48
0.53
1.6
1.9
—
—
—
0
0
12
83
1.48
0.53
5.1
6.4
23.6
24.8
mmol/l
0.59
12
83
17
127
1.38
0.52
2.6
2.5
67.9
66.3
g/l
0.35
17
114
93
860
1.19
0.48
3.3
3.3
55.8
49.1
u/l
0.32
79
808
5
33
1.53
0.41
1.8
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
4.9
—
—
—
0
0
10
71
1.44
0.40
1.2
1.9
—
—
—
0
0
9
66
1.38
0.39
1.2
1.6
—
—
—
0
0
25
209
1.23
0.37
1.1
1.3
25.4
37.2
iu/ml
—
10
70
16
127
1.29
0.35
4.1
2.8
3.9
4.5
kpa
0.86
16
119
6
90
0.65
0.33
2.7
1.7
—
—
—
0
0
63
584
1.13
0.28
2.1
2.1
97.1
92.9
pmol/l
0.24
26
326
22
191
1.18
0.23
4.6
5.0
30.4
32.0
%
0.37
14
122
5
41
1.23
0.22
6.2
1.9
23.4
24.9
mmol/l
—
5
34
5
42
1.20
0.21
1.2
1.2
—
—
—
0
0
5
42
1.20
0.21
1.2
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
4.5
—
141.2
—
0
11
0
10
0.00
0.21
0.0
1.7
—
13.7
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
197.4
—
0
13
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
6
49
1.23
0.20
2.0
1.8
—
—
—
0
0
6
52
1.16
0.19
2.3
2.0
—
—
—
0
0
15
174
0.85
0.19
1.5
1.4
—
—
—
0
0
63
598
1.09
0.17
3.8
4.0
127.9
47.9
ng/l
0.55
50
442
9
80
1.13
0.15
4.4
3.2
1.3
0.1
e6/l
—
9
80
7
90
0.77
0.15
2.7
2.5
1.0
1.4
%
—
7
90
5
45
1.11
0.10
1.6
1.9
—
—
—
0
0
5
48
1.04
0.09
2.4
3.3
—
—
—
0
0
10
96
1.04
0.00
2.2
1.6
—
—
—
0
0
45
445
1.02
0.00
2.1
2.0
174.1
228.3
u/l
0.51
40
417
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
10.6
—
0
5
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
12.1
—
0
9
0
7
0.00
0.00
0.0
2.3
—
13.7
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
5
56
0.89
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
1023.0
—
0
7
0
7
0.00
0.00
0.0
5.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
5.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_KIDNEY_CHROMOPHOBE – Chromophobe cell carcinoma of kidney
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).